Sponsors (9)
Introduced June 18, 2025 by Bill Cassidy · Last progress June 18, 2025
The bill increases and stabilizes funding, broadens surveillance and recovery supports, and strengthens workforce and safety measures to tackle overdoses more comprehensively — but does so at higher federal cost, with added administrative burden, privacy tradeoffs, and potential implementation or access risks for certain treatments.
State, Tribal, and local governments and the nonprofits and providers they fund gain predictable multi‑year authorizations and higher funding for overdose prevention, recovery, training, and workforce programs (FY2026–2030), improving program stability and planning.
People and communities at risk of overdose gain broader prevention and surveillance (including wastewater and non-opioid substances like fentanyl and xylazine), enabling earlier detection of emerging threats and more comprehensive prevention responses.
People with substance use disorders, including those seeking recovery, benefit from expanded recovery supports, peer specialist professional development, and increased tribal peer-program funding, improving access and quality of recovery services.
Taxpayers face higher federal spending because multiple programs are reauthorized with increased funding levels for FY2026–2030, raising budgetary costs without guaranteed outcomes.
States, Tribes, local grantees, HHS and administrators will incur greater administrative burden from new reporting, mandated reviews, evaluations, and implementation requirements, which can divert staff time and program resources.
Expanded surveillance authorities (e.g., wastewater and broader substance monitoring) create privacy and civil‑liberties risks if data collection, use, or safeguards are unclear or insufficient.
Based on analysis of 8 sections of legislative text.
Reauthorizes and raises funding for overdose prevention, treatment, recovery, and surveillance programs (FY2026–2030), broadens scope beyond opioids, and requires HHS reviews including buprenorphine–naloxone data.
Updates federal public-health law to expand and reauthorize programs that prevent and respond to overdoses, treat substance use disorder, support recovery services, and strengthen surveillance and technical assistance. It converts several open-ended or prior-year authorizations into specific dollar amounts for fiscal years 2026–2030, raises funding for several grant programs (including maternal residential treatment, loan repayment, and peer recovery supports), broadens surveillance language from “opioids” to “substances causing overdose,” and requires multiple HHS reviews and reports. Also directs federal reviews of certain buprenorphine–naloxone products with possible scheduling actions, adjusts pharmacy delivery rules for some controlled substances tied to administration or REMS requirements, and creates a regional recovery technical assistance center with a required evaluation and sunset in 2030. Many changes affect state and tribal grant programs, public health labs, treatment providers, and people with mental health and substance use needs.